GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Citius Pharmaceuticals
Citius Pharmaceuticals is a biotech company with a diversified portfolio. Its stock price reflects the progress of each of its drug candidates. The chart is a history of risk management and the hopes for success of at least one of its pipelines, particularly its product Mino-Lok.
Share prices of companies in the market segment - General oncology therapy
Citius Pharmaceuticals is a pharmaceutical company developing drugs to treat oncology and related conditions, as well as to combat infections. We've classified it in the "General Oncology" segment. The chart below shows how investors value companies with a diversified portfolio.
Broad Market Index - GURU.Markets
Citius Pharmaceuticals is a biopharmaceutical company developing drugs to treat cancer and related conditions. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Citius shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CTXR - Daily change in the company's share price Citius Pharmaceuticals
For Citius Pharmaceuticals, Inc., a biopharmaceutical company, daily price change is a measure of the high volatility typical of the sector. This metric reflects the market's reaction to drug development news and serves as a risk assessment parameter.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Citius Pharmaceuticals, Inc. is a pharmaceutical company. This chart shows the sector's high volatility. Comparing it to CTXR, with its diversified portfolio, helps us understand how this impacts its stability.
Daily change in the price of a broad market stock, index - GURU.Markets
Citius Pharmaceuticals is a pharmaceutical company with a diversified development portfolio, including in oncology. Its shares react to news across multiple clinical programs. This complex, multi-factor dynamic contributes uniquely to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Citius Pharmaceuticals
For Citius Pharmaceuticals, year-over-year performance is a reflection of its late-stage pipeline. Its 12-month market cap is entirely dependent on FDA decisions on its drugs, particularly the Mino-Lok catheter lock. Regulatory approval will be a fundamental step in transforming the company from an R&D company into a commercial enterprise.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company with a diversified portfolio. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Citius Pharmaceuticals, a late-stage drug developer, is a company where regulatory approval is crucial. Its performance against the market is determined by the anticipation of the FDA's verdict. A positive decision could trigger explosive growth, far outpacing the market, while a rejection would plunge the stock regardless of market conditions.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Citius Pharmaceuticals
Citius Pharmaceuticals is a late-stage biopharmaceutical company. Its monthly performance is entirely dependent on news about its key drugs, particularly Mino-Lok. FDA interactions, clinical trial data, and anticipation of commercial launch are the main events causing significant fluctuations.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
This chart reflects the dynamics of the biotech sector, particularly in oncology. For Citius, a late-stage company, it's the backdrop. Its movements reflect investor expectations surrounding the potential approval of its drugs, which could be a major event.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Citius Pharmaceuticals is a pharmaceutical company with a diversified portfolio of late-stage drugs, including treatments for cancer and infections. Assessing its prospects requires analyzing each of its products. A market-wide chart provides only the backdrop for this diverse, yet risky, company.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Citius Pharmaceuticals
Citius Pharmaceuticals, a biopharmaceutical company with a diversified late-stage pipeline, is news-sensitive. Its weekly stock price reflects progress in clinical trials of its drugs, ranging from oncology (Mino-Lok) to hemorrhoid treatment, and expectations of FDA decisions.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Citius Pharmaceuticals operates in the volatile biopharmaceutical sector, where investor sentiment often impacts all players. M&A news or general regulatory changes can lift or derail the entire sector. The chart will show whether CTXR is moving with the industry or whether its diversified portfolio is creating its own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Citius Pharmaceuticals, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on FDA decisions. The chart below clearly demonstrates how CTXR shares can live their own life, separate from the broader market, moving on their own news.
Market capitalization of the company, segment and market as a whole
CTXR - Market capitalization of the company Citius Pharmaceuticals
The Citius Pharmaceuticals chart tells the story of a diversified approach to pharmaceuticals. The company's market cap, which has several late-stage drug candidates, reflects investors' assessments of the likelihood of approval for each. Its dynamics reflect a bet that at least one of the products will reach market.
CTXR - Share of the company's market capitalization Citius Pharmaceuticals within the market segment - General oncology therapy
Citius Pharmaceuticals is a biopharmaceutical company with a diversified late-stage pipeline, including drugs for the treatment of cancer and infections. Its sector share reflects this mature strategy. The chart shows how the market assesses its chances of quickly commercializing several products.
Market capitalization of the market segment - General oncology therapy
Citius Pharmaceuticals develops and commercializes therapeutic products for the treatment of cancer and infectious diseases. The chart below shows the market capitalization of the oncology sector. This represents the risky but vital pursuit of new drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Citius Pharmaceuticals is a late-stage biopharmaceutical company with a diversified pipeline of candidates, ranging from oncology to infectious diseases. Its market capitalization reflects this pipeline. The chart below shows the economic weight of companies with multiple pipelines.
Book value capitalization of the company, segment and market as a whole
CTXR - Book value capitalization of the company Citius Pharmaceuticals
Citius Pharmaceuticals is built on a late-stage pipeline. The company's book value consists of the rights to several drug candidates, including the catheter-rescue drug Mino-Lok, and the cash flow needed to bring them to market. The chart below shows how the company uses its capital to bring its products to commercialization.
CTXR - Share of the company's book capitalization Citius Pharmaceuticals within the market segment - General oncology therapy
Citius Pharmaceuticals, a biopharmaceutical company, is focused on R&D. Its laboratories are its primary physical asset. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for a company in the research stage.
Market segment balance sheet capitalization - General oncology therapy
Citius Pharmaceuticals is a late-stage pharmaceutical company focused on oncology and infectious diseases. Its assets include intellectual property and clinical trial data. The chart shows that its balance sheet is still "light," but closer to commercialization than early-stage startups.
Book value of all companies included in the broad market index - GURU.Markets
Citius' assets comprise a pipeline of developments for the treatment of cancer and infections. The company's book value reflects its rights to several late-stage products, including a catheter-rescue treatment and a therapy for acute respiratory distress syndrome. This provides the material basis for addressing important unmet medical needs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Citius Pharmaceuticals
Citius Pharmaceuticals develops drugs to treat oncology and related conditions. Its book value is cash. Its market capitalization is a valuation of its lead drug candidates, particularly Mino-Lok, and their chances of approval and commercial success.
Market to book capitalization ratio in a market segment - General oncology therapy
Citius Pharmaceuticals is a pharmaceutical company with a diversified late-stage pipeline. The chart shows how the market assesses the likelihood of approval and commercial potential of its key products relative to its current pipeline.
Market to book capitalization ratio for the market as a whole
Citius Pharmaceuticals is a pharmaceutical company with a diversified late-stage pipeline, including drugs for the treatment of cancer and infections. Its value is the sum of the potential of its various products. The chart shows how the market values a company with several assets close to commercialization.
Debts of the company, segment and market as a whole
CTXR - Company debts Citius Pharmaceuticals
Citius Pharmaceuticals, a biopharmaceutical company, uses debt to advance its late-stage drug candidates. This chart shows the company's funding to complete clinical trials and prepare for potential commercialization of its products in oncology and the treatment of catheter-associated infections.
Market segment debts - General oncology therapy
Citius Pharmaceuticals is a late-stage biopharmaceutical company with several product candidates in its pipeline. Preparing for commercialization, including establishing manufacturing and distribution facilities, requires significant investment. This chart shows the company's financial position at this crucial stage before potential market entry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Citius Pharmaceuticals
Citius Pharmaceuticals is a pharmaceutical company with a diversified development portfolio. This chart illustrates its financial strategy. For a company running multiple clinical programs simultaneously, debt can be a way to accelerate research across all fronts, but it also diversifies and increases overall financial risk.
Market segment debt to market segment book capitalization - General oncology therapy
Citius Pharmaceuticals is a pharmaceutical company with a diversified pipeline of developments in oncology and infectious diseases. This pharmaceutical industry chart reflects how companies finance their long-term research programs. It provides context for assessing the company's financial strategy and risks in its quest to develop new drugs.
Debt to book value of all companies in the market
Citius Pharmaceuticals is a pharmaceutical company developing drugs to treat oncology and infectious diseases. This chart, showing the market's debt-to-book value ratio, is important for assessing the investment climate. The market's willingness to finance companies with long and expensive development cycles determines Citius's future.
P/E of the company, segment and market as a whole
P/E - Citius Pharmaceuticals
Citius Pharmaceuticals is a pharmaceutical company with a diversified late-stage pipeline, including drugs for the treatment of cancer and infectious diseases. This chart reflects investor valuations of its mature assets. The performance of this metric depends on the likelihood of regulatory approval, which could quickly transform the company from a research-based company to a commercial one.
P/E of the market segment - General oncology therapy
Citius Pharmaceuticals is a biotech company. This chart shows the average P/E for the biotech sector. Comparing the company's P/E to this benchmark helps understand how the market values its late-stage pipeline—whether it considers them more or less promising than the industry average.
P/E of the market as a whole
Citius Pharmaceuticals is a pharmaceutical company developing a portfolio of products for the treatment of critical conditions in oncology and infectious diseases. Its strategy is to bring drugs to market that address niche but important needs. This chart illustrates the risk appetite in biotech. The company's valuation depends on the success of its late-stage clinical trials and the commercial prospects of its lead candidates.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Citius Pharmaceuticals
Citius Pharmaceuticals is a pharmaceutical company with a diversified portfolio of late-stage drugs targeting oncology and infectious diseases. The graph reflects revenue expectations, which are contingent on FDA approvals and successful market launches.
%20P%2FE%20Citius%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Citius-Pharmaceuticals&v=1772593258487 "Chart of the company's future (projected) P/E Citius Pharmaceuticals")
Future (projected) P/E of the market segment - General oncology therapy
Citius Pharmaceuticals is a pharmaceutical company with a diversified late-stage pipeline targeting cancer and infectious diseases. This chart shows how its future revenue expectations compare to the industry average, reflecting its assessment of its multi-product launch strategy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772593258489 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Citius Pharmaceuticals is a late-stage biopharmaceutical company with a pipeline of oncology and critical care products. Its valuation hinges on the likelihood of approval and commercial launch of these products. This is a story close to its conclusion, less dependent on overall market sentiment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772593258501 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Citius Pharmaceuticals
Citius Pharmaceuticals is a late-stage pharmaceutical company developing and commercializing therapeutic products for critical conditions. Its financial metrics reflect the costs of conducting key clinical trials and preparing for product launch. This chart shows the company's financial path to potential commercialization.
Profit of companies in the market segment - General oncology therapy
Citius Pharmaceuticals is a late-stage pharmaceutical company focused on developing drugs for oncology and related therapeutic areas. This chart reflects the overall profitability of its sector. The company's success depends on the approval and commercialization of its key products, which can significantly impact its overall profitability.
Overall market profit
Citius Pharmaceuticals is a late-stage pharmaceutical company focused on developing drugs for the treatment of critical conditions in oncology and infectious diseases. Its success depends on regulatory approval and subsequent commercialization. This chart illustrates common economic cycles, as Citius transitions from development to sales.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Citius Pharmaceuticals
Citius Pharmaceuticals is a late-stage pharmaceutical company focused on products for the treatment of cancer and related conditions. The future revenue projections reflected herein are based on a high probability of approval and commercialization of its lead drug candidates, which address unmet medical needs.
%20profit%20of%20the%20company%20Citius%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Citius-Pharmaceuticals&v=1772593258609 "Graph of future (projected) profit of the company Citius Pharmaceuticals")
Future (predicted) profit of companies in the market segment - General oncology therapy
Citius Pharmaceuticals, Inc. is a late-stage pharmaceutical company focused on developing and commercializing products for the treatment of critical conditions and cancer. This chart shows revenue projections for the oncology sector. It reflects expectations for the rapid market launch of new drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772593258630 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Citius Pharmaceuticals develops drugs for the treatment of cancer and infections. As with any biotech company, the overall market revenue forecast is important for their investment appeal. Economic growth expectations, reflected in the graph, facilitate raising capital for costly clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772593258696 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Citius Pharmaceuticals
Citius Pharmaceuticals is a pharmaceutical company with a diversified late-stage pipeline. The company does not yet have stable revenue. P/S will become key after the approval of its first products, such as those for the treatment of catheter-associated infections.
P/S market segment - General oncology therapy
Citius Pharmaceuticals is a late-stage pharmaceutical company with a diversified pipeline of candidates targeting cancer and infectious diseases. This chart shows how the market assesses the combined potential of their near-commercialization products and their chances of regulatory approval to generate future revenue.
P/S of the market as a whole
Citius Pharmaceuticals is a biotech company with a diversified late-stage pipeline, including drugs for the treatment of cancer and infections. The company does not yet have sales revenue. This chart, based on actual revenue, highlights that Citius's valuation is based on the rapid approval and commercialization of its products.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Citius Pharmaceuticals
Citius Pharmaceuticals develops and commercializes therapeutic products for critical care and cancer treatment. Its pipeline includes several late-stage candidates. This chart reflects investor expectations for future revenue from its most promising developments, such as a catheter-rescue agent.
%20P%2FS%20Citius%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Citius-Pharmaceuticals&v=1772593259157 "The graph of the company's future (projected) P/S Citius Pharmaceuticals")
Future (projected) P/S of the market segment - General oncology therapy
Citius Pharmaceuticals, Inc. is a late-stage pharmaceutical company focused on developing products for the treatment of critical conditions and cancer. This chart shows how the market assesses the future commercial potential of its lead candidates. It compares it to other oncology companies, reflecting expectations for the approval and launch of its drugs.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772593259177 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Citius Pharmaceuticals is a pharmaceutical company with a diversified pipeline targeting cancer and healthcare-associated infections. This chart shows investors' overall revenue forecasts, and CTXR exemplifies how companies are addressing important unmet medical needs, attracting investor attention.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772593259251 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Citius Pharmaceuticals
Citius Pharmaceuticals is a late-stage pharmaceutical company developing and commercializing therapeutic products for the treatment of critical conditions and cancer. Because its lead candidates are on track for approval, sales revenue in this graph is minimal or nonexistent, but may include revenue from licensing agreements.
Sales of companies in the market segment - General oncology therapy
Citius Pharmaceuticals is a pharmaceutical company with a diversified late-stage pipeline. At this stage, its revenue, if any, may be derived from partnerships. This chart allows investors to assess the financial flows supporting the company on its path to commercialization.
Overall market sales
Citius Pharmaceuticals is a pharmaceutical company developing products to treat critical illnesses and cancer. The need for these treatments is not dependent on the economic situation. This schedule is not a factor for Citius, whose success is determined by the results of clinical trials and the ability to address an unmet medical need.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Citius Pharmaceuticals
Citius Pharmaceuticals is a pharmaceutical company with a diversified late-stage pipeline, including drugs for the treatment of cancer and infections. Its revenue outlook is dependent on the approval and commercialization of its key candidates. This chart shows analyst expectations for its upcoming product launches.
%20sales%20of%20the%20company%20Citius%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Citius-Pharmaceuticals&v=1772593259575 "Schedule of future (projected) sales of the company Citius Pharmaceuticals")
Future (projected) sales of companies in the market segment - General oncology therapy
Citius Pharmaceuticals is a pharmaceutical company developing and commercializing therapeutic products for the treatment of oncology and infectious diseases. This chart reflects projected revenues for the entire oncology segment. It allows for estimating market growth, which is important for assessing the potential of Citius's drug portfolio.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772593259622 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Citius Pharmaceuticals is a late-stage pharmaceutical company focused on products for the treatment of cancer and infections. Its future depends on regulatory approval and successful market launches. This graph of overall market expectations reflects the investment climate, which is important for funding commercialization and further research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772593259723 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Citius Pharmaceuticals
Citius Pharmaceuticals is a late-stage pharmaceutical company with several product candidates. This timeline depicts its path to commercialization. Future profitability depends on regulatory approval for its drugs, particularly its catheter-saving treatment and cancer therapy.
Market segment marginality - General oncology therapy
Citius Pharmaceuticals is a pharmaceutical company specializing in the development and commercialization of novel therapeutic products for the treatment of critical illnesses and cancer. This chart depicts the average profitability of the oncology sector. It provides insight into the potential profitability of Citius' innovative products, such as Mino-Lok, in this highly competitive market.
Market marginality as a whole
Citius Pharmaceuticals is a late-stage pharmaceutical company focused on developing products for the treatment of critical conditions and cancer. This gross margin schedule is irrelevant to Citius's valuation, which is determined by the likelihood of approval of its drug candidates and their commercial potential.
Employees in the company, segment and market as a whole
Number of employees in the company Citius Pharmaceuticals
Citius Pharmaceuticals is a late-stage pharmaceutical company with a diversified product portfolio. The growth of its team, especially in anticipation of potential drug approvals, reflects its preparation for commercial launch. This chart shows how the company is ramping up its resources to transition from R&D to sales.
Share of the company's employees Citius Pharmaceuticals within the market segment - General oncology therapy
Citius Pharmaceuticals is a pharmaceutical company specializing in the development and commercialization of therapeutic products for critical conditions. This chart demonstrates its focus on complex medical problems. It reflects the proportion of clinicians and researchers working on developing drugs for the treatment of cancer and catheter-related infections that Citius has.
Number of employees in the market segment - General oncology therapy
Citius Pharmaceuticals, Inc. is a pharmaceutical company developing products for the treatment of critical illnesses and cancer. This chart shows employment in the oncology therapeutics sector. The growing number of specialists in this field reflects the urgent need for new treatments for cancer-related complications and the search for more effective anticancer agents.
Number of employees in the market as a whole
Citius Pharmaceuticals, Inc. is a pharmaceutical company specializing in the development and commercialization of therapeutic products for the treatment of critical conditions and cancer. Development in this segment requires robust clinical research. This chart shows overall employment, and these companies contribute to innovative medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals is a biopharmaceutical company with a diversified portfolio. Its score on this chart is the average potential score for several developments. It reflects how the market evaluates the team's ability to manage multiple R&D projects simultaneously and bring them to commercialization.
%20of%20the%20company%20Citius%20Pharmaceuticals%20(CTXR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Citius-Pharmaceuticals-CTXR&v=1772593260356 "Chart of market capitalization per employee (in thousands of dollars) of the company Citius Pharmaceuticals (CTXR)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Citius Pharmaceuticals is a company developing drugs for the treatment of critical illnesses and cancer. Its market value per employee reflects investor valuations of its late-stage pipeline, such as Mino-Lok. This high valuation reflects high expectations for the commercialization of its key products.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772593260361 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Citius Pharmaceuticals is a pharmaceutical company developing a portfolio of drugs for the treatment of critical conditions and cancer. Having multiple products in development diversifies risks. This chart shows how the market assesses the overall potential of this portfolio and the team's ability to bring at least one of these products to market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772593260426 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals is a late-stage biotech company preparing to commercialize its lead product (Mino-Lok) for the treatment of catheter infections. This graph is likely negative, but it shows how much the company is spending on personnel in anticipation of commercialization, hoping for future profits.
%20Chart%20Citius%20Pharmaceuticals%20(CTXR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Citius-Pharmaceuticals-CTXR&v=1772593260495 "Company Profit Per Employee (in thousands of dollars) Chart Citius Pharmaceuticals (CTXR)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Citius Pharmaceuticals is a pharmaceutical company developing and commercializing therapeutic products for the treatment of critical illnesses and cancer. This chart reflects the potential value of their pipeline. It shows how highly profitable a successful product targeting unmet medical needs could be, which is a measure of their scientific and commercial strategy.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772593260530 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Citius Pharmaceuticals is a biotech company with a diversified portfolio, including drugs for cancer (Mino-Lok) and hemorrhoids. Being in late-stage development, this chart reflects the clinical trial investment per employee required to obtain FDA approval and begin commercialization.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772593260624 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals is a late-stage pharmaceutical company. This graph doesn't reflect commercial performance until its products are launched. It symbolizes potential. Successful approval and sales launch will lead to a sharp increase in this metric, demonstrating the value of its developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Citius-Pharmaceuticals-CTXR&v=1772593260677 "Sales chart per company employee Citius Pharmaceuticals (CTXR)")
Sales per employee in the market segment - General oncology therapy
Citius Pharmaceuticals (CTXR) is a biopharmaceutical company developing treatments in oncology and antibiotics, including a solution to prevent catheter infections (Mino-Lok). This chart shows the average revenue per employee in the pharmaceutical segment. Comparing CTXR to this benchmark shows their stage of development (R&D) and progress in commercializing their products.
Sales per employee for the market as a whole
Citius Pharmaceuticals (CTXR) is a late-stage biotech company. The company has products close to approval (Mino-Lok). This indicator is currently near zero, but investors are monitoring it in anticipation of imminent FDA approval. A successful product launch should lead to a sharp increase in this indicator, signaling the company's transition to the commercial stage.
Short shares by company, segment and market as a whole
Shares shorted by company Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals is a biotech company with a diversified late-stage pipeline, including a catheter-rescue drug (Mino-Lok) and a hemorrhoid treatment. This chart reflects skepticism. Bears are betting that, despite their apparent proximity to market, their drugs will face further delays or fail to receive FDA approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Citius-Pharmaceuticals-CTXR&v=1772593260978 "Short Shares Chart for the Company Citius Pharmaceuticals (CTXR)")
Shares shorted by market segment - General oncology therapy
Citius Pharma (CTXR) is a biotech with several assets, the main one being Mino-Lok, a treatment for saving infected catheters. This chart highlights the pessimism in the sector. The growing shorts in the industry are a bet that CTXR's product is too niche. Investors doubt Mino-Lok will become a blockbuster or fear another trial failure, which is typical for small pharma companies.
Shares shorted by the overall market
Citius (CTXR) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing CTXR won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals is a biotech company with a diversified pipeline, ranging from cancer to anti-infectives. This chart represents the "pulse" of their R&D. The "temperature" of investor interest fluctuates depending on which of their drugs is being announced. The success of one can overheat expectations for the entire company.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Citius-Pharmaceuticals-CTXR&v=1772593261102 "RSI 14 indicator chart for the company's stock Citius Pharmaceuticals (CTXR)")
RSI 14 Market Segment - General oncology therapy
Citius Pharmaceuticals is a biopharmaceutical company developing several late-stage products. Their key assets are Mino-Lok (a treatment for catheter infections) and I/ONTAK (a treatment for lymphoma). This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole.
RSI 14 for the overall market
Citius (CTXR) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CTXR (Citius Pharmaceuticals)
Citius Pharmaceuticals is a biopharmaceutical company whose key product, Mino-Lok, is designed to save infected catheters (prevent sepsis). This chart shows the speculative average 12-month price target from analysts, which is almost entirely dependent on their belief in FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CTXR-Citius-Pharmaceuticals&v=1772593261229 "A chart showing analyst consensus forecasts for the expected stock price. CTXR (Citius Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price CTXR (Citius Pharmaceuticals)
Citius Pharma is a biotech company with a late-stage pipeline, including Mino-Lok (an antibiotic for catheters). This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the price and the forecast, reflecting their confidence in FDA approval and commercial launch.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CTXR-Citius-Pharmaceuticals&v=1772593261259 "A chart showing the difference between the consensus forecast and the actual stock price. CTXR (Citius Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Citius Pharma is a biotech company focused on hospital-based problems. Its lead candidate (Mino-Lok) is designed to protect catheters from infection. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe in the commercial potential of niche hospital-based drugs.
Analysts' consensus forecast for the overall market share price
Citius Pharmaceuticals is a biotech company developing a pipeline of drugs to treat cancer and catheter-related infections. This chart shows the overall market "risk appetite." For Citius, a high-risk clinical-stage company, overall market optimism is critical to attracting the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Citius Pharmaceuticals
Citius Pharma is a biotech incubator. They don't have a single focus; they're developing a diversified R&D portfolio focused on unsolved problems, from cancer treatments (Mino-Lok for catheters) to hemorrhoids. This chart is a summary indicator of their R&D portfolio strategy. It reflects their progress in various (and unrelated) clinical trials.
AKIMA Market Segment Index - General oncology therapy
Citius Pharmaceuticals (CTXR) is a late-stage biopharmaceutical company with a diversified portfolio. They are developing drugs for cancer (Mino-Lok for catheter salvage) and hemorrhoids. The chart shows the segment average, helping investors assess how this pragmatic approach to development compares to the industry average.
The AKIM Index for the overall market
Citius Pharmaceuticals is a specialty pharmaceutical company developing products for critical care (Mino-Lok) and oncology. This chart, reflecting the market average, provides a macro backdrop. It helps assess how CTXR, which is approaching commercialization of its key asset, compares to overall economic trends.
